IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an ...

South San Francisco, California Tuesday, March 10, 2026, 17:00 Hrs [IST] ...

一名23岁男性患者因癫痫发作就诊，意外揭示了一个跨越三代家族成员、涉及多种致命性癌症的罕见遗传性疾病。在首次手术切除低级别星形细胞瘤八年之后，该患者于大脑两个独立部位“同时”出现了组织学类型与遗传背景完全不同的新发肿瘤——其中一个为多形性黄色星形细胞瘤，另一个为弥漫性星形细胞瘤，同时影像学检查还发现一处疑似椎旁神经鞘瘤的病变。面对如此复杂且罕见的颅内“多原发”肿瘤，结合其家族中黑色素瘤、脑胶质瘤及 ...

引言同样的致癌基因变异，为什么在不同器官中会引发截然不同的后果？为什么有的组织迅速陷入癌变的深渊，而有的组织却能长期保持沉默？一直以来，癌症基因组测序为我们描绘了不同癌症类型的突变图谱，但隐藏在这些突变背后的演化法则却始终晦暗不明。2月25日，《Na ...

在非小细胞肺癌（NSCLC）等多种肿瘤中，甲硫腺苷磷酸化酶（MTAP）基因缺失（MTAP-del）常与相邻的抑癌基因 CDKN2A 缺失（CDKN2A-del）同时存在，并与患者生存预后较差相关。针对 MTAP-del，可使用 PRMT5 和 MAT2A 抑制剂通过「合成致死」机制进行靶向干预，但其与包括 ...

南旧金山 - Ideaya Biosciences(NASDAQ:IDYA)周一在新闻稿中宣布,其针对MTAP缺失实体瘤的研究性MTA协同PRMT5抑制剂IDE892的1期临床试验已完成首位患者入组。这家市值29.1亿美元的生物技术公司表现亮眼,过去一年股价上涨近80%。 该试验将评估IDE892作为单药疗法在MTAP缺失实体瘤患者中的安全性、耐受性、药代动力学和药效学,包括非小细胞肺癌和胰腺癌患 ...

Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic, ...

Phothera, the leading manufacturer of FDA-cleared light therapy devices for chronic skin conditions including vitiligo, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma (CTCL), today ...

INC国际儿童脑瘤领域权威专家、世界小儿神经系统专业杂志《Child's Nervous System》现任主编Concezio Di Rocco教授发表研究《Subgroup specific structural variation across 1,000 medulloblastoma genomes》（对1000余例髓母细胞瘤基因组进行亚组特异性结构变异分析），以下为该项研究的详细内容解 ...

Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...

Chicago Faucets, a Geberit Group company and leader in commercial plumbing fittings, is making its first appearance at the 2026 PDC Summit Booth #920 - March 9-11, 2026 in Houston, Texas.  The company ...

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology ...